Kornimate/medical-research-clean huggingface dataset:
the patient expectation in dry needling and analgesia

Conditions: Neck Pain

Summary: this study will evaluate placebo mechanisms related to dry needling(dn) trying to determinate whether an additive effect occurs when dn is provided with an instructional set known to enhance placebo analgesia. external manipulation of patient expectation for receiving dn will be performed, in a similar way as has been already done in studies investigating the influence of expectation on spinal manipulative therapy interventions. the main purpose of this study will be therefore to determine, for the first time, how subjects' expectation about the effect of dn influences the resultant hypoalgesia. analgesic effects of dn will be assessed using the conditioned pain modulation (cpm) paradigm, which has not been previously evaluated in relation to dn.

just before dn intervention, participants will receive a positive or a neutral expectation instructional set regarding effects of a dn technique on pain perception. this instructional set will be randomly allocated to each patient. participants in the positive expectation group will be told that dn procedure: "is a very effective form of treatment used to treat neck-shoulder pain and it is expected to reduce your perception of pressure pain". participants in the neutral expectation group will be told that dn procedure: "is a form of treatment used to treat neck-shoulder pain that has unknown effects on your perception of pressure pain". dn intervention an experienced and trained physical therapist will provide dn to all the subjects. this researcher will be blinded to the specific expectation instructional set the participant receives. participants will receive one session of dn treatment for the active myofascial trigger points(mtrp) located at the upper trapezius muscle. they will be placed in a prone position on the examination table. solid filament needles of 0.30 mm diameter and 40 mm length will be used. the needle will be inserted into the skin over the palpated mtrp using pincer palpation, and slowly advanced perpendicularly until it reaches the mtrp and a twitch response is elicited.

Eligibility criteria:
inclusion criteria: * neck pain (≥3 months of duration) * vas of 4-5 of pain. * presence of at least one active mtrp located at the upper trapezius. exclusion criteria: * patients with previous cervical spine or shoulder surgery. * cervical spine radiculopathy or myelopathy. * systemic disease. * fibromyalgia. * pregnancy. * using sedative drugs. * needle phobia. * bleeding disorder. * anticoagulant medication. * previous experience with dn for myofascial pain. * skin lesion and infection or inflammatory oedema at the mtrps site
progressive weight loss and metabolic health

Conditions: Insulin Resistance; Obesity

Summary: this study will evaluate the potential beneficial cardiometabolic effect of moderate (5%) weight loss and progressive (5%, 10%, and 15%) weight loss in obese adults without diabetes. participants will be randomly assigned to one of 2 groups. group 1: supervised weight loss group (low-calorie diet). group 2: supervised weight maintenance group (normal diet). of those assigned to group 1, half of the participants will lose 5% of their body weight and the other half will lose 5%, 10%, and 15% of their weight over time under the guidance of a dietitian. research testing will be repeated at each time point (5%, 10%, and 15% weight loss). in group 2, research testing will be repeated after six months.


Eligibility criteria:
inclusion criteria: * obese: body mass index from 30 to 45 * insulin resistant: homa-ir score greater than or equal to 2 exclusion criteria: * diabetes * smoking * pregnancy * breastfeeding * heart failure * history of liver disease including hepatitis * alcoholism * exercise more than 2 hours per week

Keywords: obesity weight loss insulin resistance
performance of qdot micro™ catheter with ngen generator for patients with afib.

Conditions: Atrial Fibrillation

Summary: this workflow study will further evaluate the acute performance and safety of the qdot micro™ catheter in a clinical setting used in combination with ngen generator. subjects will be followed for 7 days post procedure.


Eligibility criteria:
inclusion criteria: 1. subjects diagnosed with symptomatic paroxysmal or early persistent af undergoing a catheter ablation procedure through pulmonary vein isolation. 2. age 18 or older. 3. signed the patient informed consent form (icf). exclusion criteria: 1. if the patient has had a ventriculotomy or atriotomy within the preceding twelve weeks. 2. presence of a myxoma or an intracardiac thrombus. 3. presence of prosthetic valves. 4. presence of active systemic infection 5. patient with an interatrial baffle or patch 6. women who are pregnant (as evidenced by pregnancy test if pre-menopausal), lactating, or who are of child bearing age and plan on becoming pregnant during the course of the clinical investigation.
the relationship between dizziness and neck pain

Conditions: Dizziness; Vertigo; Neck Pain

Summary: both dizziness and neck pain are common complaints in the norwegian population. the cervical spine has a highly developed proprioceptive system, which is involved in head and gaze stabilization as well as postural control. thus, it has been argued that dizziness and/or unsteadiness can occur due to loss of or inadequate stimulation of neck receptors in patients with neck pain. still, the notion of dizziness due to cervical dysfunction is a controversial topic. however, clinicians report that patients referred for dizziness often complain of neck pain, and vice versa. this study is a multi-center study including patients referred to 1) a neuro-otologic clinic due to dizziness and 2) a rehabilitation clinic due to neck pain. both clinics are tertiary care university clinics. the study explores the prevalence, severity and spectrum of symptoms as well as clinical findings in patients with various combinations of dizziness and neck pain. the aim is to see if these patient groups differ from each other in terms of clinical characteristics, symptoms and quality of life. additionally, the aim is to examine if there is a relationship between neck dysfunction and dizziness, and last, if the symptoms persist longer in patients with both dizziness and neck pain.

this is a longitudinal study with data collected at baseline, 6 months and 3 years follow-up. variables collected at baseline include age, sex, symptom variables including dizziness handicap inventory, vertigo symptom scale short form, haukeland dizziness questionnaire, visual analog scale, hospital anxiety and depression scale, rand-12, dynamic posturography, video-based head impulse test, bithermal caloric tests, neck disability index, as well as neck examinations including pressure algometry and measurements of the range of neck movements. follow-up data after 6 months include the same patient-reported outcomes as at baseline.

Eligibility criteria:
inclusion criteria for patients: * residence within the health region of western norway and * referral to the ent department of haukeland university hospital due to vertigo or * referral to nordås outpatient clinic due to neck pain lasting \> 3 months exclusion criteria for patients: * severe orthopaedic or neurologic disease affecting postural balance * inability to undergo test protocol due to physical or language barriers * quaternary referrals (vestibular schwannomas or divers with vestibular disorders) inclusion criteria for healthy controls: - employees at haukeland university hospital exclusion criteria for healthy controls: * known neurologic or vestibular disease or ongoing ear disease. * neck pain within last 3 months

Keywords: posturography quality of life pressure algometry cervicogenic dizziness
effect of television viewing and exercise on appetite, satiety, and food intake in children

Conditions: Childhood Obesity

Summary: the purpose of this study was to describe the effect of 30 min tv viewing with or without simultaneous moderate exercise using a treadmill on subsequent subjective appetite, satiation, and food intake in normal weight 9 to 14 year old children. it is hypothesized that tv viewing during exercise immediately before mealtime affects food intake regulation through its effect on the control of appetite and satiation.


Eligibility criteria:
inclusion criteria: * overall healthy, normal weight (between the 5th and 85th bmi percentile for age and gender) 9 to 14 year old boys and girls (peripubertal) born at term and at a normal birth weight, and does not receive any medications exclusion criteria: * significant learning, behavioral, or emotional difficulties, restricted diet, food allergies to test treatments

Keywords: children television exercise food intake appetite satiation
continuous endostar infusion combined with radiotherapy in esophageal cancer patients

Conditions: Esophageal Cancer

Summary: this study is to explore the clinical efficacy of continuous endostar infusion combined with radiotherapy in esophageal cancer patients.


Eligibility criteria:
inclusion criteria: * histological or cytological diagnosis of previously untreated stage i-iii esophageal cancer * measurable disease according to recist criteria * ecog performance status 0-1 * the length of esophageal carcinoma ≤ 10 cm * hematologic function: wbc ≥ 4.0×109/l, plt ≥ 80×109/l, hb ≥ 90g/l * renal function: cr ≤ 2.0×unl * hepatic function: bil ≤ 2.0×unl, alt/ast ≤ 5.0×unl exclusion criteria: * pregnant or lactating women * evidence of bleeding diathesis, serious infection * serious cardiovascular disease (congestive heart failure, uncontrollable arrhythmia, unstable angina, myocardial infarction, serious heart valve disease, resistant hypertension) * uncontrollable mental and nervous disorders

Keywords: endostar radiotherapy esophageal cancer
a study of the combination of ibrutinib plus venetoclax versus chlorambucil plus obinutuzumab for the first-line treatment of participants with chronic lymphocytic leukemia (cll)/small lymphocytic lymphoma (sll)

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell

Summary: the purpose of this study is to assess progression-free survival (pfs) from treatment with ibrutinib plus venetoclax (i+ven) compared with obinutuzumab plus chlorambucil (g-clb) as assessed by an independent review committee (irc).


Eligibility criteria:
inclusion criteria: * adult participants who are: (a) greater than or equal to (\>=) 65 years old or, (b) 18 to 64 years old and have at least 1 of the following: 1. cumulative illness rating scale (cirs) score \> 6 2. creatinine clearance (crcl) estimated less than (\<) 70 milliliter per minute (ml/min) using cockcroft-gault equation * diagnosis of chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll) that meets international workshop on chronic lymphocytic leukemia (iwcll) criteria * measurable nodal disease (by computed tomography \[ct\]), defined as at least one lymph node \> 1.5 centimeter (cm) in longest diameter * eastern cooperative oncology group (ecog) performance status (ps) grade less than or equal to (\<=) 2 * active cll/sll requiring treatment per the iwcll criteria exclusion criteria: * prior anti-leukemic therapy for cll or sll * presence of deletion of the short arm of chromosome 17 (del17p) or known tp53 mutation detected at a threshold of \>10 percent (%) variable allele frequency (vaf) * major surgery within 4 weeks of first dose of study treatment * known bleeding disorders (example, von willebrand's disease or hemophilia) * central nervous system (cns) involvement or suspected richter's syndrome
efficacy and safety of acetaminophen in postoperative pain management of infants

Conditions: Analgesic; Enhanced Recovery After Surgery; Postoperative Pain; Infant ALL; Acetaminophen

Summary: pain will bring early and long-term adverse reactions to infants. the investigators need to pay attention to whether there is pain in infants after surgery. since infants cannot self-report pain,the investigators need to use appropriate pain assessment scale to evaluate the pain of these infants, so as to understand the status of postoperative pain in children. the result of pain score not only enables investigators to understand the pain status of children, but also helps investigators to give corresponding intervention and treatment according to the pain degree of children. postoperative pain management is one of the core contents of eras. effective pain management is beneficial to the early postoperative recovery of infants and reduces the adverse reactions caused by pain. sveral studies have confirmed that the combination of acetaminophen and opioids could reduce the use of opioids after surgery. but even if opioid use is reduced, it still causes many side effects for children. this study evaluated the safety and efficacy of acetaminophen alone for postoperative analgesia in infants.


Eligibility criteria:
inclusion criteria: * informed consent was obtained from parents of children; * infants aged 0-12 months; * children who underwent abdominal and perineal surgery in the department of neonatal surgery, children's hospital affiliated to nanjing medical university and returned to the unaccompanied ward after removal of tracheal intubation. exclusion criteria: * no informed consent was obtained from parents; * known allergy or intolerance to acetaminophen; * children with liver function impairment (alanine aminotransferase/aspartate aminotransferase (alat/asat) more than three times the reference value; * children with renal insufficiency (urea and creatinine values exceeding the upper limit of reference values);
effect of continuous invasive blood pressure monitoring on postinduction hypotension in patients having major surgery

Conditions: Blood Pressure; Perioperative Hypotension; Postinduction Hypotension

Summary: this is a randomized trial (1) investigating whether continuous invasive arterial blood pressure monitoring using an arterial catheter reduces the area under a mean arterial pressure (map) of 65 mmhg within the first 15 minutes of anesthetic induction compared to intermittent arterial blood pressure monitoring using oscillometry in patients having major surgery under general anesthesia; and (2) investigating the effect of continuous invasive arterial blood pressure monitoring using an arterial catheter on cardiac output, stroke volume, and heart rate within the first 15 minutes of anesthetic induction compared to intermittent blood pressure monitoring using upper-arm cuff oscillometry in patients having major surgery under general anesthesia.

not provided

Eligibility criteria:
inclusion criteria: patients... * at least 18 years of age * scheduled for elective major surgery under general anesthesia that requires continuous invasive arterial blood pressure monitoring using a radial arterial catheter for clinical indications not related to the study exclusion criteria: * clinical indication to insert the arterial catheter before anesthetic induction ("awake arterial catheter"; this is usually the case in patients with severe cardiovascular diseases, such as heart failure or left ventricular assist device) * emergency surgery * american society of anesthesiologists physical status classification v or vi * need for femoral artery catheterization * heart rhythms other than sinus rhythm.
phase iii trial of bi 201335 (faldaprevir) in treatment naive (tn) and relapser hepatitis c virus (hcv)-human immunodeficiency virus (hiv) coinfected patients (startverso 4)

Conditions: Hepatitis C, Chronic

Summary: the aim of this trial is to evaluate the efficacy and the safety of bi 201335 given for 12 or 24 weeks in combination with pegifn/rbv given for 24-48 weeks, according to re-randomisation of early treatment success (ets) patients at 24 weeks to stop pegifn/rbv or continue pegifn/rbv until week 48. if no ets, then pegifn/rb for 48 weeks, in hcv treatment-naive or relapsers patients coinfected with hiv


Eligibility criteria:
inclusion criteria: 1. chronic hepatitis c (hcv) genotype 1 infection 2. chronic human immunodeficiency virus (hiv) -1 infection 3. hcv treatment naive or hcv treatment experienced but only relapsers 4. age 18 to 70 years 5. antiretroviral treatment naive or on stable highly active antiretroviral therapy (haart) 6. karnofsky score \>70 7. hcv viral load \>1.000 iu/ml exclusion criteria: 1. hcv infection of mixed genotype (1/2, 1/3, 1/4) 2. evidence of acute or chronic liver due to chronic hcv infection 3. hepatitis b virus (hbv) infection with presence of hbs-ag 4. active malignancy or history or malignancy within the last 5 years 5. received concomitant systemic antiviral (other than antiretroviral), hematopoietic growth factor or immunomodulatory treatment in 28 days prior enrolment. 6. decompensated liver disease,as evidenced by ascites, hepatic encephalopathy, esophageal variceal bleeding, and/or laboratory values that add up to \>/= 7 points according tho the child-turcotte-pugh classification 7. hemoglobin \</=11g/dl for women and \</= 12 g/dl for men 8. patients with stable cardiac disease and hemoglobin \<12g/dl 9. known hypersensitivity to any ingredient of the study drugs
bioequivalence study of individual atazanavir and cobicistat compared with atazanavir in fixed-dose combination with cobicistat

Conditions: Human Immunodeficiency Virus Type 1 (HIV-1)

Summary: the purpose of the study is to compare the pharmacokinetics and bioequivalence of atazanavir in a fixed-dose combination with cobicistat with that of atazanavir coadministered with cobicistat as single agents.


Eligibility criteria:
key inclusion criteria: * healthy men and women, ages 18 to 49 years * body mass index 18 to 32 kg/m\^2, inclusive * women of childbearing potential (wocbp) who were not pregnant or breastfeeding * wocbp and men who are sexually active with wocbp must use acceptable contraceptive methods key exclusion criteria: * any significant acute or chronic medical illness * current or recent (within 3 months of study drug administration) gastrointestinal tract disease * any major surgery within 4 weeks of study drug administration * any gastrointestinal tract surgery (including cholecystectomy) that could have an impact on the absorption of study drug * donation of blood to a blood bank or in a clinical study (except a screening visit) within 4 weeks of study drug administration (within 2 weeks for plasma only) * blood transfusion within 4 weeks of study drug administration * inability to tolerate oral medication, to be venipunctured, or to tolerate venous access * evidence of organ dysfunction or any clinically significant deviation from normal in physical examination or electrocardiogram (ecg) findings, vital sign measurements, or results of clinical laboratory tests, beyond what is consistent with the target population * any of the following 12-lead ecg findings prior to study drug administration, confirmed by repeat testing * pr ≥210 msec * qrs ≥120 msec * qt ≥500 msec * qtcf ≥450 msec * 2nd- or 3rd-degree a-v block or clinically relevant abnormalities in ecg findings * positive result on urine screening for drugs of abuse * positive result on blood screening for hepatitis c antibody, hepatitis b surface antigen, or hiv-1 or -2 antibody * laboratory test results indicating levels outside of the ranges specified below: * alanine aminotransferase \>upper limit of normal (uln) * aspartate aminotransferase \>uln * total bilirubin \>uln * serum creatinine \>uln
hybrid l24 new enrollment post approval study

Conditions: High Frequency Sensorineural Hearing Loss

Summary: this study evaluates the long term safety and effectiveness of the nucleus hybrid l24 implant in a group of newly implanted adults.


Eligibility criteria:
inclusion criteria: ear to be implanted: * normal to moderate hearing loss in the low frequencies with severe to profound mid to high frequency hearing loss in the ear to be implanted * cnc word recognition of 10-60% in the ear to be implanted contralateral ear: * moderately severe to profound mid to high frequency hearing loss in the contralateral ear * cnc word recognition equal to or better than that in the ear to be implanted but not more than 80% correct exclusion criteria: * not proficient in english * unwilling and/or unable to comply with the test protocol * deafness due to lesions of the acoustic nerve or central auditory pathway. * active middle-ear disease, with or without tympanic membrane perforation. * absence of cochlear development. * duration of severe to profound hearing loss of 30 years or greater
optimizing diagnosis of primary aldosteronism

Conditions: Primary Aldosteronism

Summary: to optimize the confirmatory tests for primary aldosteronism.

in this study, the investigators aim to optimize the three confirmatory tests: salt loading, captopril challenge and fludrocortisone suppression, and to confirm a better choice of confirming testing for single or combined diagnosis of primary aldosteronism. additionally, the investigators plan to collect blood and tissue samples of pa patients for genetic testing, and to proceed a long-term follow-up for further investigating the mechanism underlying pa and evaluating the cardio-cerebrovascular complications risk.

Eligibility criteria:
inclusion criteria: * with hypertension; * with adrenal diseases exclusion criteria: * pregnant or during lactation period; * under 18 yr; * bmi ≤ 19 or ≥ 35 * with cancer medical history * been through cardiovascular diseases in the past 3 months; * been through malignant arrhythmia, respiratory muscle paralysis or skeletal muscle paralysis caused by hypokalemia.

Keywords: primary aldosteronism confirmatory test hypertension